Bedell Frazier Investment Counselling’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Bedell Frazier Investment Counselling’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-63,475	Closed	-$630K	–	72
2015 Q2	$630K	Buy	63,475 +650	+1%	+$5.69K	0.25%	50
2015 Q1	$463K	Sell	62,825 -49,050	-44%	-$330K	0.19%	60
2014 Q4	$599K	Buy	111,875 +4,420	+4%	+$22.6K	0.29%	42
2014 Q3	$540K	Sell	107,455 -5,800	-5%	-$35.6K	0.25%	42
2014 Q2	$760K	Buy	113,255 +2,480	+2%	+$15.8K	0.38%	36
2014 Q1	$802K	Sell	110,775 -2,875	-3%	-$17K	0.45%	39
2013 Q4	$428K	Buy	+113,650	New	+$440K	0.2%	50

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bedell Frazier Investment Counselling's NWBO Position: Q3 2015 in Review

Bedell Frazier Investment Counselling sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2015, closing a stake of 63,475 shares — an estimated $630K sold.

Bedell Frazier Investment Counselling first reported a position in NWBO in Q4 2013 and held it in 7 quarters. The position peaked at $802K in Q1 2014. 79 funds tracked by Wall St. Rank hold NWBO as of Q3 2015.

Bedell Frazier Investment Counselling reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2015 after selling out during the quarter.
Bedell Frazier Investment Counselling sold 63,475 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2015, an estimated $630K.
Bedell Frazier Investment Counselling first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2013 and held it in 7 quarters.
Bedell Frazier Investment Counselling's Northwest Biotherapeutics, Inc. Common stock position peaked at $802K in Q1 2014.
79 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2015.

Based on Bedell Frazier Investment Counselling's 13F filing for Q3 2015, filed 9 Nov 2015.